Why Have Clinical Trials of Antioxidants to Prevent Neurodegeneration Failed? - A Cellular Investigation of Novel Phenothiazine-Type Antioxidants Reveals Competing Objectives for Pharmaceutical Neuroprotection.
about
Neuroprotection through flavonoid: Enhancement of the glyoxalase pathway.Coconut (Cocos nucifera) Ethanolic Leaf Extract Reduces Amyloid-β (1-42) Aggregation and Paralysis Prevalence in Transgenic Caenorhabditis elegans Independently of Free Radical Scavenging and Acetylcholinesterase Inhibition.Neuroprotective Natural Molecules, From Food to Brain
P2860
Why Have Clinical Trials of Antioxidants to Prevent Neurodegeneration Failed? - A Cellular Investigation of Novel Phenothiazine-Type Antioxidants Reveals Competing Objectives for Pharmaceutical Neuroprotection.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Why Have Clinical Trials of An ...... harmaceutical Neuroprotection.
@en
Why Have Clinical Trials of An ...... harmaceutical Neuroprotection.
@nl
type
label
Why Have Clinical Trials of An ...... harmaceutical Neuroprotection.
@en
Why Have Clinical Trials of An ...... harmaceutical Neuroprotection.
@nl
prefLabel
Why Have Clinical Trials of An ...... harmaceutical Neuroprotection.
@en
Why Have Clinical Trials of An ...... harmaceutical Neuroprotection.
@nl
P2093
P2860
P1476
Why Have Clinical Trials of An ...... harmaceutical Neuroprotection.
@en
P2093
Bernd Moosmann
Maike J Ohlow
Mathias Schreckenberger
Matthias Granold
Selina Sohre
P2860
P304
P356
10.1007/S11095-016-2068-0
P577
2016-11-28T00:00:00Z